Our infrastructure

Since 2008, we have developed a critical mass of influential researchers with an international reputation in key gastrointestinal and liver related topics.

Our translational programme has grown significantly since its inception; it involved 60 dedicated researchers with over £48.5M in awards (2013-15) and 37 research students.

Research expertise

We now manage 95 translational studies across a number of research groups:

  • Hepatitis C Virus (HCV) Group co-ordinates the world’s largest HCV cohort (n=11,000), has £8.5M in active grants and leads the discovery of potent, broadly neutralising human monoclonal antibodies, now patented and in trial.
  • Clostridia Research Group, underpinned by our £14.3M BBSRC/EPSRC Centre, is a world-class discovery unit in clostridial genetics, pathogenesis and synthetic biology with four recent filed patents.
  • Helicobacter Group is an international leader in Hp genetics, virulence, immunity and treatment targets whose work underpins modern Hp virulence testing.
  • UK-leading GI Epidemiology Group provides expert methodological support, and the Nottingham Clinical Trials Unit provides support for early patient-based translational studies.
  • Stem Cell Biology Group, with its specific stem cell based disease models; FRAME Alternatives Laboratory with its state-of-the-art cell biology facility (£1M) with expertise in culturing primary human cells; and the UK top-ranked School of Pharmacy, will translate GI and liver drug discovery/formulation programmes.


The Nottingham Molecular Pathology Node (NMPN) (£2.4M:EPSRC/MRC) is a joint venture with Respiratory Medicine; we are currently harnessing its computational and molecular pathology pipelines to transform multiplatform biomarker testing into clinical decision making tools.
We have strong links with the MRC/ARUK Centre (£2M) for Musculoskeletal Ageing Research resulting in internationally leading in in-vivo human, whole body physiological investigations within School of Nutritional Sciences, which underpin the development of new treatments for disorders of gastrointestinal and liver physiology and metabolism.